BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often and more quickly on sparsentan (Filspari) than irbesartan (Avapro ...

for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date ...

Early findings from the SPARTAN phase II trial, presented at the National Kidney Foundation (NKF) Spring Clinical Meeting, suggested that benefits with sparsentan (Filspari) for immunoglobulin A ...

At the National Kidney Foundation (NKF) Spring Clinical Meeting, researchers reported an interim analysis of the SPARTAN trial -- a phase II study testing sparsentan (Filspari) as first‑line the ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

It is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400 mg of sparsentan, compared to 300 mg of irbesartan ...

It is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400 mg of sparsentan, compared to 300 mg of irbesartan ...